Strut Health review

Strut Health is a Dallas-based cash-pay platform. Its terms identify Titan Health, P.A. and affiliated practices as the medical providers and distinguish their clinical role from Strut’s non-clinical services. The catalog lists compounded semaglutide, tirzepatide, sermorelin and NAD+, plus enclomiphene and menopause hormone products. Product pages describe visits, follow-ups and shipping as included, but those service features do not establish treatment effectiveness or suitability.

The selected injection pages list semaglutide at $129, tirzepatide at $149, and NAD+ at $149 per 500 mg vial. These are advertised 30-day auto-refill offers, not guarantees that every prescribed quantity has the same total. The semaglutide overview and dedicated oral product page still display different lozenge prices, so this comparison withholds a settled oral-semaglutide quote rather than choosing the cheaper page. Sermorelin is also offered as an injection or lozenge.

The FAQ says a US-licensed physician reviews the intake and that a phone consultation is not required in every state. Patients can message physicians through their account and ask customer service to arrange direct communication. The cited product pages advertise unlimited follow-ups. This is not a guarantee of a particular appointment length, response time or clinician. The reviewed sources do not establish a universal no-laboratory-testing rule, so ask which baseline and follow-up checks apply to your own prescription and whether they cost extra.

The refill terms deserve a close read. Product pages use monthly language, while the subscription policy says the full prescription amount is charged every thirty or ninety days, according to the refill schedule. Confirm the actual next charge date and interval; a thirty-day charge cycle is not identical to a calendar month. The FAQ calls for forty-eight hours’ notice before processing. The refund policy says cancellations after pharmacy processing are not refundable, and medication that has left the pharmacy cannot be returned. Damaged or defective orders have a separate replacement procedure requiring contact within two weeks of delivery.

The FDA issued a warning letter dated February 20, 2026 about Strut’s compounded semaglutide and tirzepatide marketing and depicted labels. It identified misleading impressions about the compounder and FDA evaluation. A warning letter is a record of the agency’s findings at that time; it does not establish the current status of every preparation, prove a product’s quality or substitute for verifying the actual dispensing pharmacy. The cited product pages now distinguish their compounded preparations from FDA-approved products, but those statements do not establish that FDA has closed the matter.

State availability also needs a treatment-specific check. The FAQ’s nationwide-except-Arkansas statement is explicitly dated 2024 and says some medications have narrower availability. It should not be represented as an independently confirmed current state availability. Ask whether the clinician can treat you where you are physically located and whether the named pharmacy can dispense the exact formulation there. The menopause catalog lists compounded capsules and topical products without a settled public recurring price on the reviewed page. The lowest-priced catalog item is not a GLP-1 or NAD+ price. Enclomiphene capsules and different sermorelin formats have their own prices, quantities and evidence. A lozenge and injection containing the same named molecule are not automatically equivalent in absorption or clinical effect. If you are considering more than one treatment, ask whether one clinician coordinates the plan, what extra monitoring is needed and whether combining prescriptions adds a separate fee or risk.